These drug regimens were primarily developed to improve cell-surface expression and function of the CFTR anion channel but there are limited data on whether they can directly modulate CF-related inflammation (Barnaby et al., 2018; Hisert et al., 2017). The gene discussed is CFTR; the disease is cystic fibrosis.